Skip to main content
. 2021 Dec 14;22(24):13413. doi: 10.3390/ijms222413413

Figure 2.

Figure 2

ICG−001, a Wnt inhibitor, disrupts CRC stemness and metastasis. (A) HCT116 cells were treated with increasing amounts of ICG−001 for 72 h, followed by MTT cell viability assays; (B) RT−qPCR confirming the global reductions in stemness-related gene expression levels by ICG−001 treatment (2.5 μM, 72 h). (C) Schematic view of the sphere formation assay measuring the effect of ICG−001 on the self-renewal activity of CSCs. A bar graph showing the reduction in the sphere-forming efficiency by ICG-001 treatment. (D) Schematic view (top) and results (bottom) of the LDA measuring the effect of ICG−001 on the self-renewal ability of CSCs. (E) Schematic view of the mouse model established by splenic injection to measure the effect of ICG−001 on CRC metastasis. The extent of liver metastasis was monitored by visualizing luciferase activity and (F) definitive necropsy. Representative images of gross anatomy and H&E-stained liver tissue. (G) RT−qPCR showing global reductions in metastasis- and CSC-related gene expression levels in ICG−001-treated metastatic colonies obtained from the livers of mice in the splenic injection model. *, ** and *** indicate p < 0.05, p < 0.01, and p < 0.001, respectively. CTRL, control; ICG, ICG−001.